Leonard Reyno

Leonard Reyno

Company: Pionyr Immunotherapeutics

Job title: Executive Vice President & Chief Medical Officer


PY314: Targeting Trem2 Positive Macrophages in Patients with Advanced Solid Tumors 9:00 am

• TREM2 is highly expressed on immune-suppressive TAMs within the TME, where it functions as a negative regulator of inflammatory responses • Pionyr’s humanized IgG1 afucosylated monoclonal antibody (PY314) specifically binds human TREM2 and balances the TME (‘Myeloid Tuning’) by specifically depleting TREM2+ TAMs, via antibody-dependent cell-mediated cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) •…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.